Morgan Stanley, JPMorgan, Jefferies, TD Securities and Leerink acted as joint book running managers for the offering.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYMR:
- Kymera Therapeutics price target raised to $60 from $54 at H.C. Wainwright
- Kymera Therapeutics price target raised to $59 from $55 at BTIG
- Kymera Therapeutics price target lowered to $53 from $57 at Wells Fargo
- Optimistic Outlook for Kymera Therapeutics Amid Strategic Partnerships and Strong KT-621 Prospects
- Closing Bell Movers: Micron surges on earnings, retreats on call comments